What is William Blair’s Estimate for VIGL Q1 Earnings?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Research analysts at William Blair issued their Q1 2026 EPS estimates for Vigil Neuroscience in a report issued on Thursday, March 13th. William Blair analyst S. Schram forecasts that the company will post earnings of $0.49 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience’s Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.12) EPS.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

Several other analysts also recently weighed in on VIGL. JMP Securities reissued a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. HC Wainwright lowered their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, March 14th. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, Wedbush lowered their price target on shares of Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, March 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $16.25.

Vigil Neuroscience Stock Down 0.5 %

Vigil Neuroscience stock opened at $1.97 on Monday. The company has a market capitalization of $80.53 million, a PE ratio of -0.96 and a beta of 1.82. The firm has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $2.76. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06.

Hedge Funds Weigh In On Vigil Neuroscience

Several hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. raised its stake in shares of Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after acquiring an additional 115,000 shares during the last quarter. 683 Capital Management LLC increased its position in shares of Vigil Neuroscience by 14.8% during the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company’s stock valued at $2,380,000 after buying an additional 180,420 shares during the period. Ensign Peak Advisors Inc increased its position in shares of Vigil Neuroscience by 16.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock valued at $1,195,000 after buying an additional 97,580 shares during the period. abrdn plc increased its position in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares during the period. Finally, Woodline Partners LP increased its position in shares of Vigil Neuroscience by 239.1% during the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock valued at $831,000 after buying an additional 344,614 shares during the period. 83.64% of the stock is owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.